Table I.
Agonist | Concentration | Comments/further guidance |
---|---|---|
ADP | 10 µM | Maximal, sustained aggregation expected at this concentration. If reversible aggregation seen use 30 µM. |
Adrenaline | 10 µM | Biphasic aggregation expected. If aggregation absent or reduced use 30 µM. |
Arachidonic acid | 1 mM | Maximal, sustained aggregation expected. If aggregation reduced or reversible use U46619 3 µM. |
PAR-1 receptor specific peptide (SFLLRN) | 100 µM | Maximal, sustained aggregation expected. If aggregation reduced use PAR-4 receptor specific peptide (AYPGKF; 500 µM). |
Collagen | 1 µg/ml | If aggregation reduced use 3 µg/ml. If this concentration shows reduced aggregation, use collagen related peptide (CRP) 3 µg/ml. |
Ristocetin | 1.5 mg/ml | Maximal, sustained agglutination (often biphasic) expected. If reduced consider vWF profile and GPIb levels by flow cytometry. |